DexCom(US:DXCM) Newsfileยท2025-11-10 03:45Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the upcoming lead plaintiff deadline on December 29, 2025, for a class action lawsuit related to misleading statements made by the company [1]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is December 29, 2025, which requires a motion to the Court [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company downplayed the severity of issues related to the G7 devices, leading to increased regulatory scrutiny and potential legal and financial repercussions [5]. - The lawsuit asserts that the public statements made by DexCom were materially false and misleading, resulting in investor damages when the true information became public [5].